Document is current
Any future updates will be listed below
-
Authors
Al-Ali, Haifa K. https://orcid.org/0000-0001-5009-2239
Heidel, Sarah T.
Palandri, Francesca https://orcid.org/0000-0001-8367-5668
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
- License Information
-
More Information
Article History
Received: 14 February 2026
Revised: 26 March 2026
Accepted: 20 April 2026
First Online: 5 May 2026
Competing interests
: HAA: consulting or advisory role for BMS, Novartis, AbbVie, AOP Pharma, Blueprint, GSK, Otsuka, Stemline, MSD, Takeda; research funding from BMS, Incyte, Novartis; and travel support from Alexion and Abbvie. STH: none. FP: Consultancy and honoraria from NOVARTIS, GSK, BMS, INCYTE, SANOFI, TAKEDA, SOBI, AOP. FHH: honoraria from Novartis, Abbvie, CTI, BMS, MSD, GSK, AOP, Prelude, Silence, Telios, Kartos; consulting/advisory role for Novartis, Abbvie, CTI, BMS, MSD, GSK, AOP, Prelude, Silence, Telios, Kartos, Sumitomo, Janssen; and research funding from Novartis, BMS, CTI.
